NDC 63323-485-01 - Xylocaine
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 63323-485
- Requested NDC
- 63323-485-01
- Package NDCs from labels
- 63323-485-41, 63323-485-26, 63323-485-01, 63323-485-27, 63323-485-03, 63323-485-57
- Manufacturer
- Henry Schein, Inc.
- Effective date
- 2025-11-07
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Xylocaine 1% (10mg/mL) | Henry Schein, Inc. | 2025-11-07 | HUMAN PRESCRIPTION DRUG LABEL |
| XYLOCAIN (LIDOCAINE HCl ) - HF Acquisition Co LLC, DBA HealthFirst | HF Acquisition Co LLC, DBA HealthFirst | 2025-05-07 | HUMAN PRESCRIPTION DRUG LABEL |
| Xylocaine MPF - Fresenius Kabi USA, LLC | Fresenius Kabi USA, LLC | 2025-04-22 | HUMAN PRESCRIPTION DRUG LABEL |
| XYLOCAINE - HF Acquisition Co LLC, DBA HealthFirst | HF Acquisition Co LLC, DBA HealthFirst | 2024-01-27 | HUMAN PRESCRIPTION DRUG LABEL |
| XYLOCAINE - HF Acquisition Co LLC, DBA HealthFirst | HF Acquisition Co LLC, DBA HealthFirst | 2024-01-22 | HUMAN PRESCRIPTION DRUG LABEL |
| Xylocaine 1% (10mg/mL) | General Injectables and Vaccines, inc. | 2022-12-22 | HUMAN PRESCRIPTION DRUG LABEL |
| Xylocaine MPF - Fresenius Kabi USA, LLC | Fresenius Kabi Austria | Fresenius Kabi USA, LLC | Fresenius Kabi Austria | 2021-08-25 | HUMAN PRESCRIPTION DRUG LABEL |
| Xylocaine - Cardinal Health | Cardinal Health | 2020-06-08 | HUMAN PRESCRIPTION DRUG LABEL |
| Xylocaine MPF - Cardinal Health | Cardinal Health | 2019-09-09 | HUMAN PRESCRIPTION DRUG LABEL |
| Xylocaine | REMEDYREPACK INC. | 2019-04-30 | HUMAN PRESCRIPTION DRUG LABEL |
| Xylocaine | Physicians Total Care, Inc. | 2012-02-09 | HUMAN PRESCRIPTION DRUG LABEL |
| Xylocaine - General Injectables & Vaccines, Inc | General Injectables & Vaccines, Inc | 2011-09-26 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 63323-485-01 | Xylocaine | 20 mL in 1 VIAL, MULTI-DOSE | INJECTION, SOLUTION | 20 | 13 | |
| 63323-485-03 | Xylocaine | 50 mL in 1 VIAL, MULTI-DOSE | INJECTION, SOLUTION | 50 | 13 | |
| 63323-485-27 | Xylocaine | 25 in 1 TRAY | INJECTION, SOLUTION | 25 | 13 | |
| 63323-485-57 | Xylocaine | 25 in 1 TRAY | INJECTION, SOLUTION | 25 | 13 | |
| 63323-485-26 | Xylocaine | 25 in 1 TRAY | INJECTION, SOLUTION | 25 | 7 | |
| 63323-485-41 | Xylocaine | 20 mL in 1 VIAL, MULTI-DOSE | INJECTION, SOLUTION | 20 | 7 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 63323-485 | XYLOCAINE MPF (LIDOCAINE HYDROCHLORIDE) INJECTION, SOLUTION XYLOCAINE (LIDOCAINE HYDROCHLORIDE) INJECTION, SOLUTION XYLOCAINE MPF (LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC] | 13 | Current NDC, Legacy NDC, 4 package rows | 20210831_ba082c2f-64f4-419d-9c88-74f203316e17.zip |
| 63323-485 | XYLOCAINE MPF (LIDOCAINE HYDROCHLORIDE) INJECTION, SOLUTION XYLOCAINE (LIDOCAINE HYDROCHLORIDE) INJECTION, SOLUTION XYLOCAINE (LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC] | 7 | Current NDC, Legacy NDC, 2 package rows | 20250515_4dd52202-8eef-4136-92dd-ada573b7cf74.zip |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 63323-485-01 | ML - Milliliter | 63323-485 | 55c3520d-d402-4267-87fe-ec239a7384ea | 1 | 2019-12-10 |
| 63323-485-03 | ML - Milliliter | 63323-485 | 8152cfd7-4dd8-49cd-8f86-c8e56a346d48 | 1 | 2019-12-10 |
| 63323-485-26 | ML - Milliliter | 63323-485 | 2b9ff4f4-641e-4bb5-9378-b0f143bdac48 | 1 | 2016-09-02 |
| 63323-485-27 | ML - Milliliter | 63323-485 | 84d0434d-5c06-4795-baaa-4cf67cf1a8e9 | 1 | 2012-07-24 |
| 63323-485-41 | ML - Milliliter | 63323-485 | 7ad5e0f1-7fc8-4e2c-949a-b8a6bf1a6808 | 1 | 2020-07-13 |
| 63323-485-57 | ML - Milliliter | 63323-485 | fcef2f79-20f4-4731-a3c6-7c153a2919bb | 1 | 2012-07-24 |
DailyMed Socrata Ingredients#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| SALINE NASAL | SODIUM CHLORIDE | ALAINA HEALTHCARE PRIVATE LIMITED | ed30a7f9-7132-42da-9bed-63a9b1c80ab2 | 2026-07-07 | Warnings | 451W47IQ8X |
| TopCare Health Pain Relief | LIDOCAINE HYDROCHLORIDE | Topco Associates LLC | 485b0671-da09-19d7-e063-6294a90aca5d | 2026-07-03 | Warnings | EC2CNF7XFP |
| JJ Care BURN | LIDOCAINE HYDROCHLORIDE | Nantong Health & Beyond Hygienic Products Inc. | d69ebc53-8552-449a-a973-f211328a3d3e | 2026-07-03 | Warnings | V13007Z41A |
| The Cell Salt Co. Daily Blend 12 in 1 | CALC FLUOR, CALC PHOS, CALC SULPH, FERRUM PHOS, KALI MUR, KALI PHOS, KALI SULPH, MAG PHOS, NAT MUR, NAT PHOS, NAT SULPH, SILICEA | The Cell Salt Company LLC | 55826f59-acf4-7370-e063-6394a90afed7 | 2026-07-01 | Warnings | 451W47IQ8X |
| Desert Harvest Releveum with Lidocaine | LIDOCAINE HYDROCHLORIDE | Desert Harvest, Inc | 9ad514ab-a6bd-4564-8ba3-0149032ebf36 | 2026-07-01 | Warnings | V13007Z41A |
| LIDOCAINE HYDROCHLORIDE | LIDOCAINE HYDROCHLORIDE | Henry Schein, Inc. | cfbca641-aeee-4dc8-a340-30c53d3b023b | 2026-07-01 | Warnings, Adverse reactions | 1010033 EC2CNF7XFP |
| NebuClear MD Saline | NEBUCLEAR MD SALINE | Blue Echo Care LLC | 55820ff9-7b4b-2bce-e063-6394a90a8b43 | 2026-06-30 | Warnings | 451W47IQ8X |
| NebuClear MD Saline | NEBUCLEAR MD SALINE | Blue Echo Care LLC | 55806cb8-cf92-c4e5-e063-6394a90aaa2d | 2026-06-30 | Warnings | 451W47IQ8X |
| NebuClear MD Saline | NEBUCLEAR MD SALINE | Blue Echo Care LLC | 5581d8e5-4105-e9da-e063-6394a90a316e | 2026-06-30 | Warnings | 451W47IQ8X |
| Lidovyx | LIDOCAINE 4% | V2 Pharma LLC | 4465eb60-a617-4608-9504-8b3b4c64f49e | 2026-06-30 | Warnings | V13007Z41A |
| FIRST SHIELD | BENZALKONIUM CHLORIDE, LIDOCAINE HCI | Unishield | f86f7446-b741-9f40-e053-6394a90a4422 | 2026-06-29 | Warnings | V13007Z41A |
| GNP Lidocaine Maximum Strength | LIDOCAINE HCL | AMERISOURCE BERGEN | 9f559c20-c9ac-e480-e053-2a95a90a8fce | 2026-06-29 | Warnings | V13007Z41A |
| LIDOCAINE HCI | LIDOCAINE HCI | HF Acquisition Co LLC, DBA HealthFirst | 76176d50-a987-c9f9-e053-2991aa0aea0f | 2026-06-29 | Warnings, Adverse reactions | 1010751 V13007Z41A |
| Leukotrap WB System | CPDA-1 BLOOD BAG COLLECTION SYSTEM | GVS TM INC | 54fd8a72-0527-df0c-e063-6294a90abe75 | 2026-06-24 | 2968PHW8QP | |
| Leukotrap WB System | CPDA-1 BLOOD BAG COLLECTION SYSTEM | GVS TM INC | 54fddca1-b40c-7af0-e063-6294a90a410e | 2026-06-24 | 2968PHW8QP | |
| Leukotrap WB System | CPDA-1 BLOOD BAG COLLECTION SYSTEM | GVS TM INC | 54fdf83e-f641-1f69-e063-6394a90ab750 | 2026-06-24 | 2968PHW8QP | |
| Nervionoix Pro Neuropathy Fast Acting Cream | LIDOCAINE HYDROCHLORIDE, MENTHOL,MAGNESIUM CHLORIDE | Micelle Laboratories, Incorporated | 23abdf62-03a8-4aaa-8e29-0e2585b5ade7 | 2026-06-24 | Warnings | V13007Z41A |
| MCAS Support | APIS MELLIFICA, ANTIMONIUM CRUDUM, ASCORBICUM ACIDUM, BOVISTA, CARBOLICUM ACIDUM, CHAMOMILLA, CORTISONE ACETICUM, GINKGO BILOBA, HEPAR SUIS, HISTAMINUM HYDROCHLORICUM, NATRUM MURIATICUM, QUERCETIN, RHUS TOX, SCUTELLARIA LATERIFLORA, STOMACH (SUIS), URTICA URENS | Deseret Biologicals, Inc. | af3d5f8f-6f24-4045-8730-c776ff54bcc4 | 2026-06-24 | Warnings | 451W47IQ8X |
| XYLOCAINE-MPF WITH EPI | XYLOCAINE-MPF WITH EPI | HF Acquisition Co LLC, DBA HealthFirst | c5dcb0e5-2624-9c9c-e053-2995a90a6d65 | 2026-06-19 | Warnings, Adverse reactions | NDA006488 1010688 30Q7KI53AK EC2CNF7XFP |
| LIDOCAINE HCl AND EPINEPHRINE | LIDOCAINE HCL AND EPINEPHRINE | HF Acquisition Co LLC, DBA HealthFirst | a09613b2-4337-5b52-e053-2995a90ab74b | 2026-06-19 | Warnings, Adverse reactions | 1010759 V13007Z41A |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.